Pioneering the Future of Oral Antibody Medicine
Transforming global health through revolutionary antibody technology that harnesses the body's natural defense system
2007 - WORLD'S FIRST
Revolutionizing Animal Health
We made medical history by registering the world's first oral antibody animal health treatment, specifically developed to aid in the prevention of diarrhea caused by E. coli bacteria. This groundbreaking achievement marked the beginning of a new era in therapeutic antibodies and established our platform technology that has since been distributed across multiple countries worldwide.
Safety First Philosophy
The GRAS Advantage
While regulatory agencies understandably focus on safety and potential side effects with new medications, our treatment platform stands apart. The end product is whole egg powder, with egg allergy being the only anticipated concern. This exceptional safety profile has earned our technology the "Generally Regarded As Safe" (GRAS) designation by the U.S. Food and Drug Administration - a testament to the natural foundation of our approach.
The Science Behind Our Breakthrough
Groundbreaking research has revealed that the human gut microbiome consists of trillions of bacteria - both beneficial and harmful - whose balance profoundly influences overall health. Our innovative oral therapeutic antibodies can be precisely targeted at specific microbiome disease influencers, safely eliminating their negative effects while preserving the essential balance of beneficial bacteria.
2019 - HUMAN HEALTH BREAKTHROUGH
World's First Human Oral Antibody Treatment
We achieved a major regulatory milestone with Health Canada's Letter of No Objection to proceed with a Phase 2 clinical trial for the world's first human oral antibody treatment targeting C. Difficile bacterial infection. This ongoing trial has already seen numerous patients successfully complete treatment, demonstrating the tremendous potential of our platform in addressing one of healthcare's most challenging infections.
Expanding Treatment Horizons
Proof of Concept Success
We have documented promising results from individuals successfully treating various conditions including traveler's diarrhea, arthritis, asthma, chronic acid indigestion, and IBS. These early successes represent potential pipeline targets for future formal clinical development.
Broad Therapeutic Potential
The gut microbiome's influence extends far beyond digestion. Scientific evidence increasingly links gut dysbiosis to anxiety, depression, autism, heart disease, autoimmune disorders, and even cancer. Each of these conditions represents a potential target for our targeted antibody approach.
Environmental Innovation
Our impact extends beyond human and animal health. We hold a U.S. patent for using our specialized antibodies to reduce methane emissions from ruminant farm animals - a breakthrough with significant potential for carbon credit applications and environmental sustainability.
COVID-19 RESPONSE
Harnessing Antibody Technology Against Pandemics
The COVID-19 pandemic brought antibodies into the global spotlight. As pioneers in antibody development, we are confident in our ability to apply our established technology platform to produce effective antibodies against COVID-19. Our approach envisions dual applications: as a treatment for infected patients and as a preventive measure functioning like a "biological mask" - offering protection where physical barriers fall short.
Our Vision for the Future
We stand at the forefront of a medical revolution, pioneering oral antibody treatments that harness the body's natural defense mechanisms. From our world-first animal health breakthrough to our expanding human health applications and environmental innovations, we continue to push the boundaries of what's possible in therapeutic antibody technology.